Ontario coroner's jury calls for drug safety measures
- Start with the medicine cabinet. Messner, Roberta L.; Gardner, Sylvia S.; Hurley, Mary Lou // RN;Jan93, Vol. 56 Issue 1, p51
Alerts on the possibility of patients ingesting toxic combinations of prescription and over-the-counter (OTC) drugs. Patient literacy; Medical history; Lifestyle; Diet; Habits; Use of written and verbal schedule.
- A.R.C. sells laser in Canada. // Ophthalmology Times;11/01/99, Vol. 24 Issue 21, p64
Announces that Laser Corp. has received a Medical Device License from the Canadian Health Ministry to sell the Laser PhotoLysis System in Canada. Information on the system; Other strategy to sell the system.
- Adverse drug reaction reporting. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;3/5/2013, Vol. 185 Issue 4, pE192
The article informs that hospitals and health facilities in Canada will have to comply with the Medication Management Standards set by the Canada's Ministry of Health for reporting adverse drug reactions in patients.
- Improving waiting times for surgery. Waddell, James P. // Canadian Journal of Surgery;Oct2008, Vol. 51 Issue 5, p333
The author reflects on the problems posed by restricted sources for surgical services in Canada. He presents the models that were developed to increase surgical volumes with minimal disruption, proven by high volumes of hip-and-knee replacement surgeries. He also discusses the models' common...
- World AIDS Day. // Journal of the Canadian Dental Association;Jan1999, Vol. 65 Issue 1, p12
The article focuses on the release of a report by the Canadian Federal Health Ministry entitled "Canada's Report on HIV/AIDS 1998: Shared Vision-Shared Hope on the Occasion of World AIDS Day."
- Self-injectable SC abatacept available in Canada for RA. // PharmacoEconomics & Outcomes News;8/24/2013, Issue 685, p10
The article reports on the move of the Canadian Common Drug Review, which recommended Bristol-Myers Squibb Canada's Orencia abatacept drug for rheumatoid arthritis and on the decision of Ontario's Ministry of Health to fund Rituxan rituximab to treat pemphigus vulgaris.
- Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities. Marostica, Eleonora; Van Ammel, Karel; Teisman, Ard; Boussery, Koen; Van Bocxlaer, Jan; De Ridder, Filip; Gallacher, David; Vermeulen, An // Journal of Pharmacokinetics & Pharmacodynamics;Dec2015, Vol. 42 Issue 6, p659
Safety pharmacology studies are performed to assess whether compounds may provoke severe arrhythmias (e.g. Torsades de Pointes, TdP) and sudden death in man. Although there is strong evidence that drugs inducing TdP in man prolong the QT interval in vivo and block the human ether-a-go-go-related...
- Defining 'Signal' and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions. Hauben, Manfred; Aronson, Jeffrey K. // Drug Safety;2009, Vol. 32 Issue 2, p99
Having surveyed the etymology and previous definitions of the pharmacovigilance term 'signal', we propose a definition that embraces all the surveyed ideas, reflects real-world pharmacovigilance processes, and accommodates signals of both harmful and beneficial effects. The essential...
- Canadian Regulation of Assisted Reproductive Technologies? Baylis, Francoise // Hastings Center Report;Jul/Aug2001, Vol. 31 Issue 4, p8
Discusses the Assisted Human Production Act, a proposed legislation presented by the Canadian Minister of Health on May 3, 2001. Aims of the legislation; Prohibited activities and controlled activities included in the legislation; Concerns raised with the draft legislation.